Madeline joined Dark Horse from International Society for Cell & Gene Therapy (ISCT), the global professional organization focused on the clinical translation of cell and gene therapies. At Dark Horse, Madeline supports clients with market research, competitive landscaping, diligence and commercial strategy projects.
Before joining DHC, Madeline was responsible for leading corporate revenue generation at ISCT including conference sponsorships and corporate memberships. In this role, Madeline acted as the voice of industry to ISCT leadership and worked closely with senior industry executives to develop programs that serve the diverse needs of companies across the cell and gene therapy industry. She became intimately familiar with the challenges facing the commercialization of cell and gene therapies and the importance of cross-sector collaboration to advance the availability of cell and gene therapies for patients.
Prior to focusing on industry activities at ISCT, Madeline managed the educational programs for ISCT Annual Meetings, working with key opinion leaders to curate peer reviewed programs serving the needs of all professionals involved in the clinical translation of cell and gene therapies.